These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 38259438)

  • 21. Effect of inactivated vaccine boosters against severe and critical COVID-19 during the Omicron BA.5 wave: A retrospective analysis of hospitalized patients in China.
    Gan J; Zhang H; Wu J; Liu Y; Liu P; Cheng R; Tang X; Yang L; Luo W; Li W
    J Med Virol; 2024 Feb; 96(2):e29402. PubMed ID: 38380744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
    Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Jan; 29(1):101-106. PubMed ID: 36028091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study.
    Barros FC; Gunier RB; Rego A; Sentilhes L; Rauch S; Gandino S; Teji JS; Thornton JG; Kachikis AB; Nieto R; Craik R; Cavoretto PI; Winsey A; Roggero P; Rodriguez GB; Savasi V; Kalafat E; Giuliani F; Fabre M; Benski AC; Coronado-Zarco IA; Livio S; Ostrovska A; Maiz N; Castedo Camacho FR; Peterson A; Deruelle P; Giudice C; Casale RA; Salomon LJ; Soto Conti CP; Prefumo F; Mohamed Elbayoumy EZ; Vale M; Hernández V; Chandler K; Risso M; Marler E; Cáceres DM; Crespo GA; Ernawati E; Lipschuetz M; Ariff S; Takahashi K; Vecchiarelli C; Hubka T; Ikenoue S; Tavchioska G; Bako B; Ayede AI; Eskenazi B; Bhutta ZA; Kennedy SH; Papageorghiou AT; Villar J;
    Am J Obstet Gynecol; 2024 Oct; 231(4):460.e1-460.e17. PubMed ID: 38367758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    Lind ML; Robertson AJ; Silva J; Warner F; Coppi AC; Price N; Duckwall C; Sosensky P; Di Giuseppe EC; Borg R; Fofana MO; Ranzani OT; Dean NE; Andrews JR; Croda J; Iwasaki A; Cummings DAT; Ko AI; Hitchings MDT; Schulz WL
    PLoS Med; 2022 Dec; 19(12):e1004136. PubMed ID: 36454733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
    Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Petrone D; Bressi M; Del Manso M; Siddu A; Proietti V; Battilomo S; Menniti-Ippolito F; Popoli P; Bella A; Riccardo F; Palamara AT; Rezza G; Brusaferro S; Pezzotti P;
    Vaccine; 2023 Jan; 41(1):76-84. PubMed ID: 36400660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2.
    Wu J; Shi X; Tao B; Zhan Y; Lu X; Wang J
    Int J Infect Dis; 2023 Jun; 131():26-31. PubMed ID: 36948448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
    Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
    Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan.
    Ogata T; Tanaka H; Kon A; Sakaibori N; Tanaka E
    Emerg Infect Dis; 2024 Jul; 30(7):1430-1433. PubMed ID: 38916601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak.
    Ye W; Li K; Zhao Z; Wu S; Qu H; Guo Y; Abudunaibi B; Chen W; Cai S; Chen C; Lin J; Xie Z; Zhan M; Ou J; Deng Y; Chen T; Zheng K
    Front Public Health; 2023; 11():1269194. PubMed ID: 38162626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
    Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
    Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.